Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Goldshield Group PLC
Niche pharma empire-building Cinven clinches Amdipharm and Mercury deals for £832m
The European private equity firm Cinven has acquired family-owned niche pharmaceuticals company Amdipharm of the UK for £367 million, and is planning to merge it with Mercury Pharma (formerly Goldshield Group), which it bought for £465 million last month. The two companies' combined revenues are around £250 million, and EBITA is £100 million.
Fuhrer family pulls out of Goldshield bidding following latest management offer
Goldshield's management appears to have trumped the Fuhrer family and former Goldshield CEO Ajit Patel in the battle for control of Goldshield Group with a bid valuing the UK firm at £178 million and the support of a large contingent of its shareholders.
Goldshield management team outbids Fuhrer family
Goldshield Group's management team has launched a counter-bid for the UK listed pharmaceuticals and consumer health group, offering a 2.2% premium to last week's offer from the family that owns Israel's Neopharm. The management team's bidding vehicle, Midas Bidco, is offering 460 pence per share in cash, valuing Goldshield at £169 million.
AIT raises bid for Goldshield
AIT Investments has increased its bid for Goldshield Group from 440 pence per share to 450 pence per share, valuing the company at £165.7 million.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice